What 4 Analyst Ratings Have To Say About Lyra Therapeutics
Portfolio Pulse from Benzinga Insights
In the last quarter, Lyra Therapeutics (NASDAQ:LYRA) received 4 bullish ratings from analysts. The company's average 12-month price target is $13.5, with a high of $15.00 and a low of $12.00. The average price target has increased by 3.85% over the past month.
October 06, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lyra Therapeutics received 4 bullish ratings from analysts in the last quarter, indicating a positive outlook. The average 12-month price target is $13.5, which has increased by 3.85% over the past month.
The bullish ratings from analysts indicate a positive outlook for Lyra Therapeutics. The increase in the average price target over the past month also suggests that analysts are becoming more optimistic about the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100